Area of research
Dermatology · Immunology
Research interest
Research interests include Medicine, Atopic dermatitis, Dermatology, Randomized controlled trial, Roflumilast, and Tuberous sclerosis.
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( <scp>INTEGUMENT</scp> ‐ <scp>PED</scp> ): A Phase 3 Randomized Controlled Trial
Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis
Pediatric psoriasis: Evolving perspectives
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants
Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
Tretinoin Microsphere Gel 0.04% Pump for Treating Acne Vulgaris in Preadolescents: A Randomized, Controlled Study